DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Depression; Continuous Antidepressant Abuse; Adverse Reaction to Drug

Intervention: Escitalopram (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Samsung Medical Center

Official(s) and/or principal investigator(s):
Doh Kwan Kim, PhD, M.D., Principal Investigator, Affiliation: Samsung Medical Center

Summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Clinical Details

Official title: Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks

Secondary outcome: biological value at 0 week and 8 weeks

Detailed description: The purposes of this study are: 1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning) 2. To improve the success rate of escitalopram treatment response for depressed patients

Eligibility

Minimum age: 19 Years. Maximum age: 89 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition. 2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians Exclusion Criteria: 1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg. suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Locations and Contacts

Samsung Medical Center, Kangnam, Seoul 135-710, Korea, Republic of
Additional Information

Starting date: December 2008
Last updated: June 4, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017